MultiCell Technologies Inc (MCET)

[grandeur]

According to the PR on Dec. 26, 2012
On December 18, 2012 as presented at the CIMT and ASCB, "Simona Bot, M.D. presented preclinical research results in an abstract titled "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma."


I have worked in surgery and have first hand experience on cases of hepatocellular carcinoma. Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.